Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.

    FRANKLIN, Mass., Oct. 5 /CNW/ -- Following its recent merger with Echo
Therapeutics, Inc., Sontra Medical Corporation (OTC Bulletin Board:   SONT), a
dual platform-enabled transdermal specialty therapeutics and diagnostics
company, today announced that it has changed its corporate name to Echo
Therapeutics, Inc., effective Monday, October 8, 2007. In addition, on October
8, 2007, the Company's OTC Bulletin Board ticker symbol will change to "ECTE"
and its corporate website address will become
    "Our new name better reflects our expanded strategic focus on building a
broad pipeline of advanced topical formulations of FDA-approved specialty
pharmaceutical products and next generation needle-free transdermal
diagnostics," said Patrick T. Mooney, M.D., CEO of Echo Therapeutics.
    About Echo Therapeutics
    Echo Therapeutics is a dual platform-enabled, specialty therapeutics and
diagnostics company developing an extensive pipeline of advanced topical
formulations of FDA-approved products and a suite of needle-free transdermal
diagnostics.  Echo is developing a next generation, needle-free Continuous
Transdermal Glucose Monitor (CTGM) system for use in the diabetes home care
and hospital critical care markets. Echo's next generation CTGM system
leverages its FDA-approved SonoPrep(R) ultrasound-mediated skin permeation
technology platform. Echo is also developing a broad portfolio of advanced
topical formulations of well-established, FDA-approved products using its
proprietary AzoneTS(TM) dermal penetration technology. Echo has submitted a
New Drug Application (NDA) to the FDA for the approval of its lead Azone TS-
based product, Durhalieve(TM), for the treatment of corticosteroid responsive
    SonoPrep is a registered trademark of Echo Therapeutics, Inc.
    Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995. Any forward-
looking statements contained herein are based on current expectations, but are
subject to a number of risks and uncertainties. The factors that could cause
actual future results to differ materially from current expectations include,
but are not limited to, risks and uncertainties relating to our ability to
develop, market and sell pharmaceutical or diagnostic products based on our
AzoneTS and SonoPrep platform technologies, including AzoneTS-based Durhalieve
for corticosteroid responsive dermatoses and a SonoPrep-based continuous
transdermal glucose monitor system for the diabetes and hospital critical care
markets; the availability of substantial additional equity capital to support
our robust research, development and product commercialization activities; and
the success of our AzoneTS and SonoPrep business, research, development, and
regulatory approval, marketing and distribution plans and strategies.  These
and other factors are identified and described in more detail in our filings
with the SEC, including, without limitation, our respective annual reports on
Form 10-KSB for the year ended December 31, 2006, our most recent quarterly
reports on Form 10-QSB, and our current reports on Form 8-K. Echo
Therapeutics, Inc. does not undertake to update these forward-looking

    10 Forge Parkway
    Franklin, MA 02038, USA
    Tel: 1+ 877-4-SONTRA (766878)
    Fax: 1+ 508-553-8760

    Investor Relations Contacts:
    Patrick T. Mooney, M.D., CEO

For further information:

For further information: Patrick T. Mooney, M.D., CEO of Echo 
Therapeutics, Inc., +1-508-530-0329, Web Site:        

Organization Profile


More on this organization


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890